PDS Biotechnology Corp Cash Flow Conversion Efficiency
PDS Biotechnology Corp cash flow conversion efficiency. Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has a cash flow conversion efficiency ratio of 0.780x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.79 Million) by net assets ($-3.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PDS Biotechnology Corp (2012–2025)
Cash flow conversion efficiency of PDS Biotechnology Corp from 2012 to 2025. This chart illustrates how PDS Biotechnology Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest PDS Biotechnology Corp stock price today for real-time trading data and today's change.
PDS Biotechnology Corp Cash Flow Conversion Ratio Explained
PDS Biotechnology Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PDS Biotechnology Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PDS Biotechnology Corp ranked by their cash flow conversion efficiency. Also see PDSB company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MEGA International Development Co Ltd
TWO:5529
|
0.360x |
|
BCP Investment Corp.
NASDAQ:BCIC
|
0.112x |
|
Big River Industries Ltd
AU:BRI
|
0.084x |
|
CSP Inc
NASDAQ:CSPI
|
0.010x |
|
Howteh Technology Co Ltd
TWO:3114
|
0.073x |
|
Pharol SGPS SA
LS:PHR
|
-0.001x |
|
EXA E&C Inc
KQ:054940
|
0.179x |
|
Orior AG
SW:ORON
|
0.250x |
Annual Cash Flow Conversion Efficiency for PDS Biotechnology Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of PDS Biotechnology Corp from 2012 to 2025. Review PDSB free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $9.25 Million | $-27.75 Million | -3.000x | -62.74% |
| 2024-12-31 | $19.00 Million | $-35.03 Million | -1.843x | -43.19% |
| 2023-12-31 | $26.13 Million | $-33.64 Million | -1.287x | -120.31% |
| 2022-12-31 | $44.00 Million | $-25.71 Million | -0.584x | -195.79% |
| 2021-12-31 | $63.21 Million | $-12.49 Million | -0.198x | +59.24% |
| 2020-12-31 | $27.13 Million | $-13.15 Million | -0.485x | +68.63% |
| 2019-12-31 | $11.70 Million | $-18.07 Million | -1.545x | -39.06% |
| 2018-12-31 | $29.84 Million | $-33.15 Million | -1.111x | -70.28% |
| 2017-12-31 | $62.37 Million | $-40.70 Million | -0.652x | -80.97% |
| 2016-12-31 | $89.28 Million | $-32.19 Million | -0.361x | -103.01% |
| 2015-12-31 | $122.48 Million | $-21.75 Million | -0.178x | -150.89% |
| 2014-12-31 | $-27.83 Million | $-9.71 Million | 0.349x | -33.40% |
| 2013-12-31 | $-15.35 Million | $-8.04 Million | 0.524x | -21.03% |
| 2012-12-31 | $-3.38 Million | $-2.25 Million | 0.664x | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more